Predictive Hyperglycemia and Hypoglycemia Minimization: In-Home Evaluation of Safety, Feasibility, and Efficacy in Overnight Glucose Control in Type 1 Diabetes

OBJECTIVE The objective of this study was to determine the safety, feasibility, and efficacy of a predictive hyperglycemia and hypoglycemia minimization (PHHM) system compared with predictive low-glucose insulin suspension (PLGS) alone in overnight glucose control. RESEARCH DESIGN AND METHODS A 42-night trial was conducted in 30 individuals with type 1 diabetes in the age range 15–45 years. Participants were randomly assigned each night to either PHHM or PLGS and were blinded to the assignment. The system suspended the insulin pump on both the PHHM and PLGS nights for predicted hypoglycemia but delivered correction boluses for predicted hyperglycemia on PHHM nights only. The primary outcome was the percentage of time spent in a sensor glucose range of 70–180 mg/dL during the overnight period. RESULTS The addition of automated insulin delivery with PHHM increased the time spent in the target range (70–180 mg/dL) from 71 ± 10% during PLGS nights to 78 ± 10% during PHHM nights (P < 0.001). The average morning blood glucose concentration improved from 163 ± 23 mg/dL after PLGS nights to 142 ± 18 mg/dL after PHHM nights (P < 0.001). Various sensor-measured hypoglycemic outcomes were similar on PLGS and PHHM nights. All participants completed 42 nights with no episodes of severe hypoglycemia, diabetic ketoacidosis, or other study- or device-related adverse events. CONCLUSIONS The addition of a predictive hyperglycemia minimization component to our existing PLGS system was shown to be safe, feasible, and effective in overnight glucose control.

[1]  Darrell M. Wilson,et al.  A Randomized Trial of a Home System to Reduce Nocturnal Hypoglycemia in Type 1 Diabetes , 2014, Diabetes Care.

[2]  Laya Ekhlaspour,et al.  Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes: a randomised crossover trial. , 2016, The lancet. Diabetes & endocrinology.

[3]  Roman Hovorka,et al.  Home use of closed-loop insulin delivery for overnight glucose control in adults with type 1 diabetes: a 4-week, multicentre, randomised crossover study. , 2014, The lancet. Diabetes & endocrinology.

[4]  Automated Overnight Closed-Loop Control Using a Proportional-Integral-Derivative Algorithm with Insulin Feedback in Children and Adolescents with Type 1 Diabetes at Diabetes Camp. , 2016, Diabetes technology & therapeutics.

[5]  Tadej Battelino,et al.  MD-Logic Overnight Control for 6 Weeks of Home Use in Patients With Type 1 Diabetes: Randomized Crossover Trial , 2014, Diabetes Care.

[6]  Ahmad Haidar,et al.  Outpatient overnight glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or conventional insulin pump therapy in children and adolescents with type 1 diabetes: an open-label, randomised controlled trial. , 2015, The lancet. Diabetes & endocrinology.

[7]  Janet M. Allen,et al.  Day and Night Closed-Loop Control in Adults With Type 1 Diabetes , 2013, Diabetes Care.

[8]  J. Giedt,et al.  Rensselaer Polytechnic Institute , 1960, Nature.

[9]  Claudio Cobelli,et al.  2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial. , 2015, The lancet. Diabetes & endocrinology.

[10]  David M Nathan,et al.  Outpatient glycemic control with a bionic pancreas in type 1 diabetes. , 2014, The New England journal of medicine.

[11]  Darrell M. Wilson,et al.  Inpatient Studies of a Kalman-Filter-Based Predictive Pump Shutoff Algorithm , 2012, Journal of diabetes science and technology.

[12]  B. Buckingham,et al.  Day-and-Night Closed-Loop Control Using the Unified Safety System in Adolescents With Type 1 Diabetes at Camp , 2016, Diabetes Care.

[13]  R. Tanenberg,et al.  Confirmation of hypoglycemia in the "dead-in-bed" syndrome, as captured by a retrospective continuous glucose monitoring system. , 2010, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[14]  The Diabetes Control and Complications Trial (DCCT): Design and Methodologic Considerations for the Feasibility Phase , 1986, Diabetes.

[15]  Hypoglycemia does not change the threshold for arousal from sleep in adolescents with type 1 diabetes. , 2012, Diabetes technology & therapeutics.

[16]  Howard C. Zisser,et al.  Feasibility of Outpatient Fully Integrated Closed-Loop Control , 2013, Diabetes Care.

[17]  Ahmad Haidar,et al.  Closed-Loop Basal Insulin Delivery Over 36 Hours in Adolescents With Type 1 Diabetes , 2013, Diabetes Care.

[18]  Malgorzata E. Wilinska,et al.  Overnight Closed-Loop Insulin Delivery in Young People With Type 1 Diabetes: A Free-Living, Randomized Clinical Trial , 2014, Diabetes Care.

[19]  Dale E. Seborg,et al.  Randomized Crossover Comparison of Personalized MPC and PID Control Algorithms for the Artificial Pancreas , 2016, Diabetes Care.

[20]  Marc D. Breton,et al.  Multinational Home Use of Closed-Loop Control Is Safe and Effective , 2016, Diabetes Care.

[21]  Roman Hovorka,et al.  Day and Night Home Closed-Loop Insulin Delivery in Adults With Type 1 Diabetes: Three-Center Randomized Crossover Study , 2014, Diabetes Care.

[22]  Janet M. Allen,et al.  Day and Night Closed-Loop Control in AdultsWith Type 1 Diabetes A comparison of two closed-loop algorithms driving continuous subcutaneous insulin infusion versus patient self-management , 2013 .

[23]  Bruce Buckingham,et al.  Response to nocturnal alarms using a real-time glucose sensor. , 2005, Diabetes technology & therapeutics.

[24]  B. Wayne Bequette,et al.  Predictive Low-Glucose Insulin Suspension Reduces Duration of Nocturnal Hypoglycemia in Children Without Increasing Ketosis , 2015, Diabetes Care.

[25]  Janet M. Allen,et al.  Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies , 2011, BMJ : British Medical Journal.

[26]  E. Atlas,et al.  Nocturnal glucose control with an artificial pancreas at a diabetes camp. , 2013, The New England journal of medicine.

[27]  Multinight "bedside" closed-loop control for patients with type 1 diabetes. , 2015, Diabetes technology & therapeutics.

[28]  Roman Hovorka,et al.  Home Use of an Artificial Beta Cell in Type 1 Diabetes. , 2015, The New England journal of medicine.

[29]  Darrell M. Wilson,et al.  Outpatient safety assessment of an in-home predictive low-glucose suspend system with type 1 diabetes subjects at elevated risk of nocturnal hypoglycemia. , 2013, Diabetes technology & therapeutics.

[30]  D. B. Keenan,et al.  The Use of an Automated, Portable Glucose Control System for Overnight Glucose Control in Adolescents and Young Adults With Type 1 Diabetes , 2012, Diabetes Care.

[31]  Benyamin Grosman,et al.  Day and Night Closed-Loop Control Using the Integrated Medtronic Hybrid Closed-Loop System in Type 1 Diabetes at Diabetes Camp , 2015, Diabetes Care.

[32]  Roman Hovorka,et al.  Closing the loop overnight at home setting: psychosocial impact for adolescents with type 1 diabetes and their parents , 2014, BMJ Open Diabetes Research and Care.

[33]  Marc D. Breton,et al.  Overnight Glucose Control With an Automated, Unified Safety System in Children and Adolescents With Type 1 Diabetes at Diabetes Camp , 2014, Diabetes Care.

[34]  D. BretonMarc,et al.  Multinight "bedside" closed-loop control for patients with type 1 diabetes. , 2015 .

[35]  T. Jones,et al.  Decreased epinephrine responses to hypoglycemia during sleep. , 1998, The New England journal of medicine.

[36]  Marc D. Breton,et al.  Safety of Outpatient Closed-Loop Control: First Randomized Crossover Trials of a Wearable Artificial Pancreas , 2014, Diabetes Care.